Immune reconstitution inflammatory syndrome: Difference between revisions

Jump to navigation Jump to search
Line 23: Line 23:


*[[Lamivudine]]
*[[Lamivudine]]
*[[Ritonavir]]
* [[Zidovudine]]
* [[Zidovudine]]



Revision as of 17:38, 17 January 2015

Sexually transmitted diseases Main Page

AIDS Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating AIDS from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

HIV Opportunistic Infections

HIV Coinfections

HIV and Pregnancy

HIV Infection in Infants

Diagnosis

Diagnostic Study of Choice

AIDS Case Definition

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Nutrition
Drug Resistance

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

HIV Vaccine

Case Studies

Case #1

Immune reconstitution inflammatory syndrome On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Immune reconstitution inflammatory syndrome

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Immune reconstitution inflammatory syndrome

CDC on Immune reconstitution inflammatory syndrome

Immune reconstitution inflammatory syndrome in the news

Blogs on Immune reconstitution inflammatory syndrome

Directions to Hospitals Treating AIDS

Risk calculators and risk factors for Immune reconstitution inflammatory syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: Immune reconstitution syndrome; IRIS; IRS

Overview

Immune reconstitution inflammatory syndrome (IRIS) or immune reconstitution syndrome (IRS) is a condition seen in some cases of AIDS or immunosuppression, in which the immune system begins to recover, but then responds to a previously acquired opportunistic infection with an overwhelming inflammatory response that paradoxically makes the symptoms of infection worse.

The suppression of CD4 T cells by HIV (or by immunosuppressive drugs) causes a decrease in the body's normal response to certain infections. Not only does this make it more difficult to fight the infection; it may mean that a level of infection that would normally produce symptoms is instead undetected (subclinical infection). If the CD4 count rapidly increases (due to effective treatment of HIV, or removal of other causes of immunosuppression), a sudden increase in the inflammatory response produces nonspecific symptoms such as fever, and in some cases a worsening of damage to the infected tissue.

Though these symptoms can be dangerous, they also indicate that the body may now have a better chance to defeat the infection. The most common treatment is to administer antibiotic or antiviral drugs against the infectious organism, and in some cases corticosteroids to suppress inflammation until the infection has been eliminated.

Infections most commonly associated with IRIS include cytomegalovirus, herpes zoster, Mycobacterium avium complex (MAC), Pneumocystis pneumonia, and tuberculosis. AIDS patients are more at risk for IRIS if they are starting HAART for the first time, or if they have recently been treated for an opportunistic infection. It is generally advised that when patients have low initial CD4 T cell count and opportunistic infection at the time of their HIV diagnosis, they receive treatment to control the opportunistic infections before HAART is initiated.

IRIS in cryptococcal meningitis

IRIS has been described in immunocompetent hosts who have meningitis caused by Cryptococcus gattii and Cryptococcus neoformans var. grubii, environmental fungi which often affect immunocompetent hosts. Several weeks or even months into appropriate treatment, there is a sudden onset deterioration with worsening meningitis symptoms and progression or development of new neurological symptoms.

Causes

Drug Side Effect

Reference

  • Shelburne, S.A., Visnegarwala, F., Darcourt, J., Graviss, E.A., Giordano, T.P., White Jr., A.C. and Hamill R.J. (2005) Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 19, 399-406. PMID 15750393

External link

Template:WikiDoc Sources